EU Backs Leqembi, Marking Potential Breakthrough in Alzheimer's Treatment
Key Insights
The European Union's drug regulator recommends approval for Leqembi, developed by Eisai and Biogen, potentially becoming the first approved Alzheimer's (search) treatment in the EU.
Leqembi's approval is recommended for Alzheimer's (search) patients with one or no copies of the ApoE4 (search) gene variant, typically linked to earlier disease onset.
EU member states will decide on pricing and reimbursement, considering national health system contexts and the potential use of Leqembi, if marketing authorization is granted.
The European Union drugs regulator has recommended the approval of Leqembi, an Alzheimer's (search) drug developed by Eisai and Biogen, marking a significant step toward potentially offering the first approved Alzheimer's treatment in the EU. This decision brings renewed hope to millions of patients and their families affected by this debilitating disease.
The recommendation specifies that Leqembi is intended for patients with either one or no copy of the ApoE4 (search) gene variant, a genetic factor often associated with an earlier onset of Alzheimer's (search). The decision was based on a re-examination by the EU regulator, which concluded that the drug's benefits outweigh the risks, particularly concerning brain swelling, in patients with fewer ApoE4 genes.
Pricing and Reimbursement Decisions Await
Should the European Commission grant marketing authorization, individual EU member states will then determine the pricing and reimbursement strategies for Leqembi. These decisions will take into account each nation's specific healthcare system context and the potential utilization of the drug within their respective populations.
Optimism Amidst Prior Concerns
Health experts are expressing optimism about Leqembi, viewing it as a potential ray of hope for EU patients and their families. This positive outlook comes despite previous concerns surrounding the drug's risk of brain swelling, a factor that has been carefully considered in the regulatory review process.